Compare Recursion Pharmaceuticals Inc (RXRX) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Seagate Technology Holdings PLC — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B), while Seagate Technology Holdings PLC trades at $783 (market cap $176.19B). The key difference: Seagate Technology Holdings PLC is far larger — about 82.3× Recursion Pharmaceuticals Inc's market cap, and Seagate Technology Holdings PLC pays a 0.38% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Seagate Technology Holdings PLC for 41 Days on average.
| RXRX | STX | |
|---|---|---|
Market Cap | $2.14B | $176.19B |
Volume | 30,789,535 | 5,061,875 |
Sector | Health | Technology |
52-Week High | $6.79 | $1.09K |
52-Week Low | $2.84 | $211.63 |
Typical Hold Time | 22 Days | 41 Days |
Enterprise Value | $1.66B | $178.34B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Seagate Technology (STX) trades at $807.34, up 0.21% with bearish technical signals despite strong fundamental performance. The company reported Q2 2026 EPS of $5.71, beating estimates by 12%, and maintains robust profitability with 26.11% net margins. Recent news highlights competitive pressures as Toshiba plans to expand AI storage production, potentially challenging Seagate's pricing power in the high-capacity drive market.
While analyst consensus remains bullish with a $1,130 price target, near-term risks include increased competition and volatile cash flows. The stock's elevated valuation ratios (P/E 58.1, P/S 15.16) require sustained earnings growth justification, particularly as technical indicators signal caution with resistance at $816.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
